Thrombosis and Circulation: From Bench to Bedside
Thrombosis and Circulation Research, EarlyView.
Zhenguo Zhai
wiley +1 more source
Cardiotoxicity of BRAF/MEK inhibitors
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe +4 more
wiley +1 more source
Association of rheumatoid arthritis with major adverse cardiovascular events despite normal myocardial perfusion imaging. [PDF]
Frohlich BA +10 more
europepmc +1 more source
Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes +7 more
wiley +1 more source
Assessing Coronary Calcium Thresholds on Attenuation-Correction CT With Myocardial Perfusion Imaging Equating to Secondary Prevention. [PDF]
Kyriakoulis I +10 more
europepmc +1 more source
Abstract Background and Purpose Doxorubicin (DOX) is a highly effective anthracycline, whose clinical application for cancer is limited by cardiotoxicity. The mechanisms underlying doxorubicin‐induced toxic cardiomyopathy (DICM) involve electrophysiological remodelling with intracellular Na+ overload because of increased late INa and hyperactivation of
Anna‐Lena Feder +7 more
wiley +1 more source
Type of dialysis may influence the prognostic value of myocardial perfusion imaging in end stage renal disease: an observational [<sup>13</sup>N]NH<sub>3</sub> PET/CT study. [PDF]
Wenning C +4 more
europepmc +1 more source
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source
Utility of stress parameters to determine prognosis following normal exercise SPECT myocardial perfusion imaging. [PDF]
Shirazi Z +6 more
europepmc +1 more source
Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights
Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra +5 more
wiley +1 more source

